dBurkholderia pseudomallei, the causative agent of melioidosis, has complex and poorly understood extracellular and intracellular lifestyles. We used transposon-directed insertion site sequencing (TraDIS) to retrospectively analyze a transposon library that had previously been screened through a BALB/c mouse model to identify genes important for growth and survival in vivo. This allowed us to identify the insertion sites and phenotypes of negatively selected mutants that were previously overlooked due to technical constraints. All 23 unique genes identified in the original screen were confirmed by TraDIS, and an additional 105 mutants with various degrees of attenuation in vivo were identified. Five of the newly identified genes were chosen for further characterization, and clean, unmarked bpsl2248, tex, rpiR, bpsl1728, and bpss1528 deletion mutants were constructed from the wild-type strain K96243. Each of these mutants was tested in vitro and in vivo to confirm their attenuated phenotypes and investigate the nature of the attenuation. Our results confirm that we have identified new genes important to in vivo virulence with roles in different stages of B. pseudomallei pathogenesis, including extracellular and intracellular survival. Of particular interest, deletion of the transcription accessory protein Tex was shown to be highly attenuating, and the tex mutant was capable of providing protective immunity against challenge with wild-type B. pseudomallei, suggesting that the genes identified in our TraDIS screen have the potential to be investigated as live vaccine candidates.
Burkholderia pseudomallei is a Gram-negative, motile saprophytic bacterium that is the causative agent of melioidosis. This emerging human pathogen is endemic to the soil and water of tropical areas, including Thailand, Singapore, and northern Australia, and can cause infection through contact with broken skin or through ingestion or inhalation of the bacterium (1). The resulting disease can manifest as a localized skin ulcer or can progress to a systemic infection that is associated with mortality rates as high as 50% in some regions of endemicity (2). There is currently no licensed vaccine against B. pseudomallei available, and it is highly resistant to most antibiotics, severely limiting treatment options (3). Due to the virulent nature of the pathogen, potential for aerosol transmission, and lack of therapeutic options, B. pseudomallei is listed as a Tier 1 bioterrorism threat by the Centers for Disease Control and Prevention (4).B. pseudomallei is a facultative intracellular pathogen capable of invading and replicating within both epithelial cells and macrophages (5). While B. pseudomallei is capable of extracellular growth and survival and is highly resistant to complement-mediated killing in human sera, intracellular growth is essential for virulence (2, 6). When B. pseudomallei enters the host cell, either through phagocytosis or by inducing its own uptake into nonphagocytic cells, it is able to escape from the phagosome or endocyt...